Orasis Pharmaceuticals announced the completion of a $78 million Series D financing round to support the commercial launch of its presbyopia eye drop, Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%.

The funding round includes a $68 million equity investment co-led by Arboretum Ventures and Johnson & Johnson Innovation. Additional support came from investors, such as Catalio Capital Management, Freepoint Capital Group, and returning backers Visionary Ventures, Bluestem Capital, SBI (Japan) Innovation Fund, Sequoia Capital, and Maverick Ventures, alongside individual contributors. Additionally, Orasis secured $15 million in structured capital from Catalio Capital Management, with $10 million available at closing. 

Orasis received FDA approval for Qlosi in October 2023.